The safety and efficacy of etelcalcetide for the treatment of secondary hyperparathyroidism compared with cinacalcet

The safety and efficacy of etelcalcetide for the treatment of secondary hyperparathyroidism compared with cinacalcet - The safety and efficacy of etelcalcetide compared with cinacalcet

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027344

Enrollment

Registered

2017-05-15

Start date

2017-05-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients on maintenance hemodialysis treated with cinacalcet for secondary hyperparathyroidism

Interventions

etelcalcetide (5mg - 10mg) every hemodialysis session 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with secondary hyperparathyroidism who are undergoing maintenance hemodialysis

Exclusion criteria

Exclusion criteria: Nothing

Design outcomes

Primary

Measure	Time frame
iPTH, Ca, P, side effect, dosage of etelcalcetide	—

Countries

Japan

Contacts

Public ContactTakahiro Yajima

Matsunami general hospital Department of nephrology

yajima5639@gmail.com058-388-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026